Last update 01 Nov 2024

Nihon Servier Co., Ltd.

Private Company|
Tokyo-to, Japan
|
www.nihonservier.co.jp

Overview

Tags

Neoplasms
Immune System Diseases
Hemic and Lymphatic Diseases
Small molecule drug
Enzyme

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Immune System Diseases2
Hemic and Lymphatic Diseases2
Endocrinology and Metabolic Disease1
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug1
Enzyme1
Top 5 TargetCount
ASN(Asparagine)1
TOP1(DNA topoisomerase I)1

Related

2
Drugs associated with Nihon Servier Co., Ltd.
Pegaspargase
Target
ASN
Mechanism
ASN inhibitors
Active Org.
Servier Pharmaceuticals LLCServier Pharmaceuticals LLCStartup [+5]
Originator Org.
Enzon Pharmaceuticals, Inc.Enzon Pharmaceuticals, Inc.
Active Indication
Lymphoma [+4]
Inactive Indication
Solid tumor
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date01 Feb 1994
Irinotecan Hydrochloride
Target
TOP1
Mechanism
TOP1 inhibitors
Active Org.
Eli Lilly & Co.Eli Lilly & Co. [+13]
Originator Org.
Yakult Honsha Co., Ltd.Yakult Honsha Co., Ltd.
Active Indication
Pancreatic adenocarcinoma metastatic [+30]
Inactive Indication
Adenocarcinoma [+46]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date19 Jan 1994
3
Clinical Trials associated with Nihon Servier Co., Ltd.
JPRN-UMIN000053191 / RecruitingNot Applicable
Oncaspar I.V. Infusion 3750 General Drug Use-Results Survey (Acute lymphocytic leukemia, malignant lymphoma) - Oncaspar General Drug Use-Results Survey (Acute lymphocytic leukemia, malignant lymphoma)
JPRN-UMIN000041934 / CompletedNot Applicable
observational study for patients with pancreatic cancer - observational study for patients with pancreatic cancer
JPRN-UMIN000041015 / CompletedNot Applicable
Onivyde I.V. infusion 43 mg General Drug Use-Results Survey (Unresectable pancreatic cancer after disease progression following cancer chemotherapy) - Onivyde General Drug Use-Results Survey (Pancreatic cancer)
100 Clinical Results associated with Nihon Servier Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Nihon Servier Co., Ltd.
Login to view more data
100 Deals associated with Nihon Servier Co., Ltd.
Login to view more data
100 Translational Medicine associated with Nihon Servier Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Irinotecan Hydrochloride
 ( TOP1 )		Pancreatic Cancer
More
Approved
Pegaspargase
 ( ASN )		Lymphoma
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free